Fast Five Quiz: Obesity-Related Hypertension

Michael Weber, MD

Disclosures

August 09, 2022

In June 2021, the FDA approved the use of the GLP-1 receptor agonist semaglutide for weight loss, in a 2.4-mg/week subcutaneous dose. The drug is indicated as an adjunct to diet and exercise for adults with an initial BMI ≥ 30 kg/m2 (obesity) and for BMI ≥ 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes, or dyslipidemia). The approval was based on four phase 3 clinical trials in the STEP program involving approximately 4500 patients. The STEP 1, 2, and 4 trials reported a 15%-18% weight loss over 68 weeks in individuals with overweight or obesity who received the medication.

Phentermine, another GLP-1 receptor agonist, is available for short-term (8-12 weeks) adjunctive use as part of weight reduction regimen based on exercise, behavioral modification, and caloric restriction in management of exogenous obesity for patients with initial BMI ≥ 30 kg/m² or ≥ 27 kg/m² in presence of other risk factors (eg, controlled hypertension, diabetes, and hyperlipidemia).

Learn more about medications in the treatment and management of obesity.

Editor's Recommendations

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....